Avita Medical Initiates FDA Study of Its ReCell® Spray-On-Skin™ for Reconstructive and Aesthetic Indications

Published: May 16, 2012

NORTHRIDGE, Calif. & CAMBRIDGE, England--(BUSINESS WIRE)--Avita Medical Ltd. (ASX: AVH), (OTC: AVMXF), (OTCQX: AVMXY),the regenerative medicine company, today announced that it has commenced enrolment in the US FDA-approved feasibility study for the use of ReCell® Spray-On-Skin™ in the treatment of hypertrophic dyspigmented scars (raised and/or discoloured scars).

Back to news